Gilead Profit Misses Wall Street Expectations As COVID Drug Sales Decline-To The Moon - Tiger Brokers Online Investing Community - To The Moon

8
Comment
Favorite

Gilead Profit Misses Wall Street Expectations As COVID Drug Sales Decline

Reuters2023-04-28

April 27 (Reuters) - Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.

Sales of the hospital-administered drug also know as remdesivir plunged 63% to $573 million for the quarter, well off analysts' estimates of $697.6 million. The company said the steep decrease was due to lower rates of COVID-19 hospitalizations in all regions.

Gilead reported a profit of $1.37 per share excluding items in the quarter ended March 31, compared to analyst expectations of $1.54 per share, according to Refinitiv data.

Sales excluding Veklury rose 15% to $5.7 billion in the first quarter due to strength in its HIV treatments and cell therapy for cancer.

Sales of Gilead's HIV portfolio rose 13% to $4.19 billion, with Biktarvy bringing in $2.7 billion, above Wall Street estimates of $2.53 billion.

Gilead left its full-year adjusted earnings forecast unchanged at $6.60 to $7.00 per share.

Its shares fell 2.4% in extended trading to $81.50.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

8

Report

Comment

empty

No comments yet

Most Discussed

7x24

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2330557136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-28 08:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2330557136","market":"us","top_or_hot":-1,"title":"Gilead Profit Misses Wall Street Expectations As COVID Drug Sales Decline","media":"Reuters","content":"<html><head></head><body><p>April 27 (Reuters) - Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.</p><p>Sales of the hospital-administered drug also know as remdesivir plunged 63% to $573 million for the quarter, well off analysts&#39; estimates of $697.6 million. The company said the steep decrease was due to lower rates of COVID-19 hospitalizations in all regions.</p><p>Gilead reported a profit of $1.37 per share excluding items in the quarter ended March 31, compared to analyst expectations of $1.54 per share, according to Refinitiv data.</p><p>Sales excluding Veklury rose 15% to $5.7 billion in the first quarter due to strength in its HIV treatments and cell therapy for cancer.</p><p>Sales of Gilead&#39;s HIV portfolio rose 13% to $4.19 billion, with Biktarvy bringing in $2.7 billion, above Wall Street estimates of $2.53 billion.</p><p>Gilead left its full-year adjusted earnings forecast unchanged at $6.60 to $7.00 per share.</p><p>Its shares fell 2.4% in extended trading to $81.50.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Profit Misses Wall Street Expectations As COVID Drug Sales Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Profit Misses Wall Street Expectations As COVID Drug Sales Decline\n</h2>\n\n<h4 class=\"meta\">\n\n2023-04-28 08:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 27 (Reuters) - Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"2330557136","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2330557136","pubTimestamp":1682641959,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 27 (Reuters) - Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter pr","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"由于COVID药品销量下降，Gilead利润低于华尔街预期","themeId":"ec9f6f0df2b6498587e7f5318b2eff2b","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"April 27 (Reuters) - Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%.Sales of the hospital-administered drug also know as remdesivir plunged 63% to $573 million for the quarter, well off analysts' estimates of $697.6 million. The company said the steep decrease was due to lower rates of COVID-19 hospitalizations in all regions.Gilead reported a profit of $1.37 per share excluding items in the quarter ended March 31, compared to analyst expectations of $1.54 per share, according to Refinitiv data.Sales excluding Veklury rose 15% to $5.7 billion in the first quarter due to strength in its HIV treatments and cell therapy for cancer.Sales of Gilead's HIV portfolio rose 13% to $4.19 billion, with Biktarvy bringing in $2.7 billion, above Wall Street estimates of $2.53 billion.Gilead left its full-year adjusted earnings forecast unchanged at $6.60 to $7.00 per share.Its shares fell 2.4% in extended trading to $81.50.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}